|
|
Volumn 356, Issue 6334, 2017, Pages 125-127
|
|
Epidemic insurance
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EBOLA VACCINE;
VIRUS VACCINE;
BIOTECHNOLOGY;
DISEASE CONTROL;
DISEASE INCIDENCE;
DISEASE TREATMENT;
DRUG DEVELOPMENT;
EBOLA VIRUS DISEASE;
EPIDEMIC;
EPIDEMIOLOGY;
HEALTH INSURANCE;
PHARMACEUTICAL INDUSTRY;
VACCINE;
AFRICA;
ANTHRAX;
ASIA;
AUTOIMMUNE DISEASE;
AVIAN INFLUENZA;
DRUG INDUSTRY;
EBOLA HEMORRHAGIC FEVER;
EPIDEMIC;
HUMAN;
IMMUNE RESPONSE;
INFECTION;
LIFE THREAT;
PRIORITY JOURNAL;
PUBLIC HEALTH;
SEVERE ACUTE RESPIRATORY SYNDROME;
SHORT SURVEY;
INSURANCE;
ORGANIZATION AND MANAGEMENT;
POLICY;
UNITED STATES;
VIRUS INFECTION;
DRUG INDUSTRY;
EPIDEMICS;
HUMANS;
INSURANCE;
POLICY;
UNITED STATES;
VIRAL VACCINES;
VIRUS DISEASES;
|
|
EID: 85018520646
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.356.6334.125 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|